🟣 Pentoxifylline improves blood flow by decreasing blood viscosity and improving red blood cell flexibility, which can affect circulatory dynamics.

🟣 When combined with antihypertensives, there is a risk of additive hypotension, meaning blood pressure may drop more than intended.

🟣 A significant blood pressure drop can reduce perfusion further, causing dizziness, syncope, or falls, especially in older adults.

🟣 Close monitoring is important because the patient may not recognize early signs of hypotension such as lightheadedness or weakness.

🟣 This interaction risk makes antihypertensive therapy a key “red flag” when assessing for adverse effects after starting pentoxifylline.

Antibiotic:

🟣Most antibiotics do not have a predictable additive effect with pentoxifylline on blood pressure or bleeding risk in routine practice.

🟣Monitoring may be needed based on the specific antibiotic, but it is not the most typical class concern here.

Antilipemic:

🟣Lipid-lowering agents are important for long-term vascular protection but are not the main concern for acute additive adverse effects with pentoxifylline.

🟣They do not typically create a rapid hemodynamic interaction requiring close monitoring.

Antipsychotic:

🟣Antipsychotics can cause hypotension on their own, but the classic nursing priority with pentoxifylline is monitoring when combined with blood pressure–lowering therapy.

🟣The question targets the most likely medication class prompting close adverse-effect surveillance.

🟡 Cilostazol is used for intermittent claudication and works by improving blood flow to the extremities through antiplatelet effects and vasodilation.

🟡 The hallmark symptom of PVD-related claudication is leg cramping with walking, caused by inadequate oxygen supply during exertion.

🟡 If cilostazol is effective, the patient should experience improved walking distance and reduced pain/cramping during activity.

🟡 This statement directly reflects improved functional perfusion to exercising leg muscles, which is the main treatment goal of cilostazol therapy.

🟡 Reduced claudication improves mobility, supports exercise tolerance, and helps the patient engage in walking programs that further enhance collateral circulation.

“My blood pressure has decreased.”

🟡Cilostazol is not prescribed primarily to treat hypertension, and BP reduction is not the best indicator of effectiveness for claudication.

🟡Effectiveness is measured by improved walking tolerance and reduced ischemic leg pain.

“I have had fewer episodes of angina.”

🟡Cilostazol is not a primary antianginal therapy and should not be judged by chest pain reduction.

🟡The medication is targeted toward lower-extremity perfusion and claudication symptoms.

“My pulse rate is more regular.”

🟡Heart rhythm regularity is unrelated to the primary goal of cilostazol therapy.

🟡The best effectiveness indicator is decreased exercise-induced leg pain.

History of heart disease:

🔵 A history of heart disease helps identify systemic atherosclerosis, since PVD often coexists with coronary artery disease.

🔵 This information guides risk stratification for serious complications like MI and stroke, which are strongly associated with vascular disease.

🔵 It supports safe planning for activity and procedures because cardiac comorbidity affects treatment tolerance.

🔵 Knowing cardiac history assists in medication planning, since many therapies overlap (antiplatelets, statins).

🔵 It establishes a baseline for recognizing worsening vascular disease and cardiovascular instability.

Current medications:

🔵 Reviewing current medications identifies therapies affecting perfusion (antihypertensives, antiplatelets) and bleeding risk.

🔵 It helps detect interactions and contraindications, especially when adding drugs like cilostazol or pentoxifylline.

🔵 Medication review supports accurate baseline assessment of symptom control—some drugs may mask or improve symptoms.

🔵 It also reveals adherence patterns that influence disease progression and outcomes.

🔵 A complete list improves safety and helps tailor PVD education to the patient’s current regimen.

Smoking and dietary habits:

🔵 Smoking is a major modifiable factor that accelerates atherosclerosis and worsens peripheral circulation through vasoconstriction.

🔵 Dietary habits influence lipid levels and inflammation, both central to plaque buildup and progression.

🔵 Baseline habits guide individualized teaching for long-term prevention and symptom reduction.

🔵 Identifying triggers and risks helps target interventions that improve vascular health and walking tolerance.

🔵 This assessment supports measurable goals (cessation, lipid control, heart-healthy nutrition) to slow disease progression.

Limb pain:

🔵 Limb pain assessment identifies classic intermittent claudication and helps determine severity, location, and functional limitation.

🔵 Pain pattern (exertional vs rest pain) helps distinguish worsening ischemia and potential critical limb ischemia.

🔵 It provides a symptom baseline for evaluating treatment effectiveness, especially with walking programs or medications.

🔵 Pain severity may indicate urgent complications requiring escalation (rest pain can signal severe perfusion deficit).

🔵 Accurate pain assessment also supports safety planning to prevent falls and promote mobility.

Weight:

🔵 Weight is part of baseline cardiovascular risk assessment because obesity contributes to hypertension, dyslipidemia, and insulin resistance.

🔵 Weight trends also reflect nutritional status and overall health, which affects tissue healing and circulation.

🔵 It provides data for lifestyle planning, including realistic exercise targets and dietary counseling.

🔵 Weight supports monitoring for fluid shifts or edema that may complicate vascular status.

🔵 Tracking weight helps guide long-term interventions that reduce vascular burden and improve outcomes.

Mental status:

🔵Mental status can be relevant in overall assessment, but it is not a core baseline focus specific to PVD severity and perfusion status.

🔵PVD baseline assessment centers more on vascular risk factors, symptoms, and limb perfusion findings.

🟠 Heparin is an anticoagulant that increases bleeding risk by enhancing antithrombin activity, preventing clot formation.

🟠 Protamine sulfate is the specific antidote that binds to heparin and neutralizes its anticoagulant effect, helping restore clotting ability.

🟠 In a trauma patient with profuse bleeding, reversing heparin quickly is critical to reduce ongoing hemorrhage and prevent shock.

🟠 Protamine is given cautiously and monitored because rapid administration can cause hypotension or allergic-type reactions, especially in high-risk patients.

🟠 The nurse prioritizes this reversal agent because it directly counteracts the medication responsible for impaired coagulation.

Vitamin K:

🟠Vitamin K reverses warfarin, not heparin.

🟠It supports synthesis of clotting factors but does not neutralize heparin’s antithrombin-mediated effect.

Enoxaparin (Lovenox):

🟠Enoxaparin is a low-molecular-weight heparin that also increases bleeding risk and would not reverse heparin.

🟠Administering it would worsen anticoagulation rather than counteract it.

Warfarin sodium (Coumadin):

🟠Warfarin is an anticoagulant that inhibits vitamin K–dependent clotting factors and would increase bleeding.

🟠It is not used as an antidote and would be dangerous in active hemorrhage.

🔴 An aPTT of 90 seconds with a control of 30 seconds is about 3× the control, indicating excess anticoagulation.

🔴 With IV heparin, an overly prolonged aPTT significantly increases the risk of serious bleeding (GI bleed, intracranial bleed, hematuria).

🔴 The most accurate immediate nursing action is to stop (hold) the heparin infusion according to typical heparin protocols and facility policy while initiating further evaluation.

🔴 After holding the drip, the nurse should promptly follow protocol steps such as notifying the provider, anticipating a dose adjustment, and preparing for repeat coagulation studies.

🔴 This intervention directly addresses the highest immediate threat: hemorrhage due to supratherapeutic anticoagulation.

Assess the patient for decreased sensorium:

🔴Neuro assessment is important, but it does not correct the urgent problem of over-anticoagulation.

🔴The priority is to prevent ongoing bleeding risk by stopping the infusion first.

Note the RBC count and wait for the provider:

🔴Waiting delays action while the patient remains at high risk for bleeding.

🔴RBC changes may occur after bleeding and are not the immediate trigger for heparin titration like aPTT is.

Document results are within therapeutic range:

🔴These results are not within range given the aPTT is markedly prolonged relative to control.

🔴Documenting as therapeutic is inaccurate and could lead to missed intervention and patient harm.

🟦 For subcutaneous enoxaparin, leaving the needle in place for about 10 seconds helps ensure the full dose is deposited into the subcutaneous tissue.

🟦 This reduces medication tracking back through the needle path, which lowers the risk of leakage and local irritation.

🟦 Enoxaparin has a significant risk of bruising/hematoma, and correct technique helps minimize tissue trauma.

🟦 Proper administration is typically in the abdomen (anterolateral/posterolateral), away from the umbilicus, using a skinfold for consistent subcutaneous delivery.

🟦 Holding the needle briefly supports accurate dosing and reduces complications like ecchymosis and localized bleeding.

Expel the air bubble:

🟦The air bubble in prefilled LMWH syringes is intended to help deliver the full dose and reduce medication leakage.

🟦Expelling it can lead to dose loss and may increase bruising from medication tracking.

Administer into the deltoid muscle:

🟦Enoxaparin is given subcutaneously, not intramuscularly, because IM injections increase the risk of hematoma.

🟦The deltoid is not an appropriate site for LMWH injection.

Massage the site after injection:

🟦Massaging increases capillary disruption and greatly increases bruising and bleeding.

🟦With anticoagulants, the site should be left alone to minimize hematoma formation.

🟣 Thromboembolic disease treatment includes drugs that either lyse existing clots (thrombolytics) or prevent extension/new clot formation (anticoagulants).

🟣 Thrombolytics (e.g., alteplase) actively break down fibrin, dissolving formed thrombi in selected urgent situations.

🟣 Anticoagulants (e.g., heparin, LMWH, warfarin, DOACs) do not dissolve existing clots, but they prevent clot propagation and allow the body to naturally dissolve the clot over time.

🟣 The combined therapeutic concept across thromboembolic drugs is preventing clot-related vessel obstruction and reducing risk of embolization (e.g., PE, stroke).

🟣 This option best captures the broad mechanism goal: remove dangerous clots when indicated and prevent new clot formation/extension.

Vasodilation and increased blood flow:

🟣Vasodilators can improve perfusion but do not directly treat clot formation or fibrin obstruction.

🟣Thromboembolic therapy targets coagulation and clot stability, not vessel diameter alone.

Preventing platelet aggregation and inhibiting clot formation:

🟣Antiplatelets help prevent arterial platelet-rich clots, but they do not dissolve established thrombi and are not the main therapy for many venous thromboembolic events.

🟣This option describes only one drug class rather than the full mechanism goal across thromboembolic therapies.

Making platelets more flexible:

🟣Platelet flexibility is not a recognized primary mechanism for thromboembolic pharmacotherapy.

🟣 The key targets are platelet aggregation and the coagulation cascade, not platelet flexibility.

🟢 Spinach is very high in vitamin K, which is essential for the synthesis of clotting factors and directly affects warfarin therapy.

🟢 Warfarin works by inhibiting vitamin K–dependent clotting factors (II, VII, IX, X), so increased vitamin K intake can reduce warfarin effectiveness.

🟢 High vitamin K foods can lower INR, increasing the risk of clot formation if the patient’s intake suddenly increases.

🟢 The key teaching is not necessarily to avoid vitamin K completely, but to keep vitamin K intake consistent to maintain stable anticoagulation.

🟢 Leafy green vegetables like spinach are classic examples of foods that can significantly influence INR stability.

Potato:

🟢Potatoes are not considered high in vitamin K compared with leafy greens.

🟢They have minimal effect on INR unless prepared with vitamin K–rich ingredients.

Fruit:

🟢Most fruits contain low vitamin K and are not the primary concern for warfarin interactions.

🟢The major dietary concern is dark leafy greens and sudden changes in intake.

Pasta:

🟢Pasta is not a high vitamin K food and does not significantly counteract warfarin in typical servings.

🟢It is not a key item in warfarin dietary teaching.